Aclaris therapeutics reports fourth quarter and full year 2023 financial results and provides a corporate update

Wayne, pa., feb. 27, 2024 (globe newswire) -- aclaris therapeutics, inc. (nasdaq: acrs), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the fourth quarter and full year of 2023 and provided a corporate update.
ACRS Ratings Summary
ACRS Quant Ranking